Compare NXL & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | TCRT |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.8M |
| IPO Year | 2022 | 2025 |
| Metric | NXL | TCRT |
|---|---|---|
| Price | $1.47 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.8K | ★ 2.6M |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.76 | 24.66 |
| EPS | N/A | ★ N/A |
| Revenue | $301,647.00 | ★ $15,900,000.00 |
| Revenue This Year | $14.37 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 78.78 | N/A |
| 52 Week Low | $0.22 | $0.72 |
| 52 Week High | $67.20 | $4.50 |
| Indicator | NXL | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 44.22 |
| Support Level | $1.31 | $1.02 |
| Resistance Level | $5.36 | $2.09 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.17 | -0.08 |
| Stochastic Oscillator | 64.29 | 7.81 |
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.